Analysis Indicates IWR Could Reach $106
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 22 2025
0mins
Source: NASDAQ.COM
ETF Analysis: The iShares Russell Mid-Cap ETF (IWR) has an implied analyst target price of $105.81, indicating a potential upside of 12.55% from its current trading price of $94.01.
Notable Holdings: Key underlying holdings with significant upside include Blue Owl Capital Inc (23.76% higher target), Ally Financial Inc (16.73% higher target), and DXC Technology Co (15.79% higher target).
Analyst Target Justification: Questions arise regarding whether analysts' targets are justified or overly optimistic, considering recent developments in the companies and their industries.
Investor Research Needed: Further research is suggested for investors to assess the validity of these analyst targets and the potential for future stock performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OWL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OWL
Wall Street analysts forecast OWL stock price to rise
15 Analyst Rating
12 Buy
3 Hold
0 Sell
Strong Buy
Current: 10.120
Low
18.00
Averages
21.13
High
28.00
Current: 10.120
Low
18.00
Averages
21.13
High
28.00
About OWL
Blue Owl Capital Inc. is an alternative asset management company. The Company deploys private capital across Credit, GP Strategic Capital and Real Estate platforms on behalf of institutional and private wealth clients. Its product platforms include Credit, GP Strategic Capital and Real Estate. Its credit products offer private financing solutions primarily to upper-middle-market companies. Its credit products are offered through a mix of business development companies, long-dated private funds, managed accounts and collateralized loan obligations. It is focused on acquiring equity stakes in or providing debt financing to private capital firms. Its Real Estate products are focused on acquiring triple net lease real estate occupied by investment-grade or creditworthy tenants. Its Real Estate products are offered through Permanent Capital vehicles, including its real estate investment trusts, and long-dated private funds. It offers asset management services to the insurance industry.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigations into Multiple Biotech Company Mergers
- Esperion Acquisition Investigation: Esperion Therapeutics is set to be acquired by ARCHIMED for $3.16 per share in cash, with potential contingent milestone payments of up to $100 million, raising concerns about whether the board breached fiduciary duties by failing to ensure fair pricing for shareholders.
- Sila Realty Acquisition Scrutiny: Sila Realty Trust will be acquired by Blue Owl Capital for $30.38 per share in an all-cash deal valued at approximately $2.4 billion, with investigations questioning whether the board adequately protected shareholder interests during the transaction process, potentially affecting fair value.
- Lisata Therapeutics Merger Investigation: Lisata Therapeutics is being acquired by Kuva Labs for $4.00 per share in cash, along with two non-tradeable rights, prompting investigations into whether the board conducted a fair process, which could impact shareholder benefits.
- SkyWater Technology Acquisition Review: SkyWater is to be acquired by IonQ for $35.00 per share in a cash-and-stock deal valued at around $1.8 billion, with investigations focusing on whether the board fulfilled its fiduciary duties, particularly as the deal price is below the company's 52-week high of $36.27.
See More
Blue Owl's Growth Outlook Remains Strong Amid Market Jitters
- Solid Loan-to-Value Ratios: Analyst Wilma Burdis noted that Blue Owl's loan-to-value ratios remain at a reasonable 70% even among riskier loans, indicating a strong equity cushion that bolsters investor confidence.
- Market Rebound Potential: Burdis emphasized that despite recent market volatility, there is significant rebound potential for Blue Owl and similar stocks, with expectations of improved performance by 2026, reflecting the company's robust fundamentals.
- Continued Institutional Investment: The analyst highlighted ongoing investments from institutional investors as a positive indicator, showcasing recognition of private credit products and further solidifying Blue Owl's market position.
- AI Infrastructure Opportunities: Blue Owl stands to benefit significantly from AI infrastructure spending, leveraging long-term partnerships with major tech firms like Meta, Google, and Amazon, which are expected to provide sustained growth momentum for the company's infrastructure lending business.
See More
Private Equity Firms Restructure Debt Amid Liquidity Concerns
- Liquidity Crisis Intensifies: Redemptions from private credit funds have surged due to fears of potential bad loans in sectors like application software, highlighting a pressing need for liquidity in a high-interest-rate environment that may lead to increased financial strain on companies.
- Debt Securitization Trend: Private equity firms are securitizing troubled loans by combining them with higher-quality debt into larger investment vehicles to extend debt maturities, a strategy reminiscent of practices seen during the 2008 financial crisis aimed at alleviating impending debt pressures.
- Rating Agency Warnings: KBRA reported a record number of companies downgraded by two or more levels in its default monitor range during the first quarter, indicating heightened market concern over default risks, even though mass defaults have not yet occurred.
- Insurance Sector Risks: As the life insurance industry deepens its involvement in private credit, Moody's warns of potential negative rating actions for insurers with high concentrations in complex, illiquid assets, thereby increasing liquidity risks across the broader financial system.
See More
Brown University Cuts Stake in Blue Owl Capital by 53%
- Stake Reduction: Brown University's $8 billion endowment cut its stake in Blue Owl Capital by 53%, reducing shares from 3.2 million to 1.5 million as of March 31, 2025, indicating a cautious approach towards the private credit sector amid market uncertainties.
- Shareholding Status: Despite the reduction in Blue Owl Capital shares, the university retained approximately 2.6 million shares in the management company, reflecting confidence in the overall business despite challenging market conditions.
- Market Environment Impact: Publicly traded BDCs like OBDC are trading at significant discounts as investor skepticism about valuations grows, particularly with retail investors and wealthy individuals withdrawing from the private credit asset class due to negative headlines.
- Investment Return Performance: The endowment achieved an 11.9% investment return in fiscal 2025, demonstrating resilience in its diversified portfolio that spans public equity, real assets, and private equity, despite facing market pressures.
See More
BLUE OWL CAPITAL: DIVERSIFIED CAPITAL RAISING IN Q1 YIELDS $11 BILLION IN NEW COMMITMENTS ACROSS ASSET CLASSES, STRATEGIES, AND CHANNELS
Capital Raising Overview: Blue Owl Capital successfully diversified its capital raising efforts across various asset classes, strategies, and channels in Q1.
Commitments Achieved: The firm secured a total of $11 billion in new capital commitments during the first quarter.
See More
UBS Increases Target Price for Blue Owl Capital Inc. to $9.5, Up from $9
- UBS Raises Price Target: UBS has increased its price target for Blue Owl Capital from $9 to $9.50.
- Market Implications: This adjustment reflects UBS's positive outlook on Blue Owl Capital's performance and potential growth in the market.
See More
Investigations into Multiple Biotech Company Mergers
- Esperion Acquisition Investigation: Esperion Therapeutics is set to be acquired by ARCHIMED for $3.16 per share in cash, with potential contingent milestone payments of up to $100 million, raising concerns about whether the board breached fiduciary duties by failing to ensure fair pricing for shareholders.
- Sila Realty Acquisition Scrutiny: Sila Realty Trust will be acquired by Blue Owl Capital for $30.38 per share in an all-cash deal valued at approximately $2.4 billion, with investigations questioning whether the board adequately protected shareholder interests during the transaction process, potentially affecting fair value.
- Lisata Therapeutics Merger Investigation: Lisata Therapeutics is being acquired by Kuva Labs for $4.00 per share in cash, along with two non-tradeable rights, prompting investigations into whether the board conducted a fair process, which could impact shareholder benefits.
- SkyWater Technology Acquisition Review: SkyWater is to be acquired by IonQ for $35.00 per share in a cash-and-stock deal valued at around $1.8 billion, with investigations focusing on whether the board fulfilled its fiduciary duties, particularly as the deal price is below the company's 52-week high of $36.27.
See More
Blue Owl's Growth Outlook Remains Strong Amid Market Jitters
- Solid Loan-to-Value Ratios: Analyst Wilma Burdis noted that Blue Owl's loan-to-value ratios remain at a reasonable 70% even among riskier loans, indicating a strong equity cushion that bolsters investor confidence.
- Market Rebound Potential: Burdis emphasized that despite recent market volatility, there is significant rebound potential for Blue Owl and similar stocks, with expectations of improved performance by 2026, reflecting the company's robust fundamentals.
- Continued Institutional Investment: The analyst highlighted ongoing investments from institutional investors as a positive indicator, showcasing recognition of private credit products and further solidifying Blue Owl's market position.
- AI Infrastructure Opportunities: Blue Owl stands to benefit significantly from AI infrastructure spending, leveraging long-term partnerships with major tech firms like Meta, Google, and Amazon, which are expected to provide sustained growth momentum for the company's infrastructure lending business.
See More
Private Equity Firms Restructure Debt Amid Liquidity Concerns
- Liquidity Crisis Intensifies: Redemptions from private credit funds have surged due to fears of potential bad loans in sectors like application software, highlighting a pressing need for liquidity in a high-interest-rate environment that may lead to increased financial strain on companies.
- Debt Securitization Trend: Private equity firms are securitizing troubled loans by combining them with higher-quality debt into larger investment vehicles to extend debt maturities, a strategy reminiscent of practices seen during the 2008 financial crisis aimed at alleviating impending debt pressures.
- Rating Agency Warnings: KBRA reported a record number of companies downgraded by two or more levels in its default monitor range during the first quarter, indicating heightened market concern over default risks, even though mass defaults have not yet occurred.
- Insurance Sector Risks: As the life insurance industry deepens its involvement in private credit, Moody's warns of potential negative rating actions for insurers with high concentrations in complex, illiquid assets, thereby increasing liquidity risks across the broader financial system.
See More
Brown University Cuts Stake in Blue Owl Capital by 53%
- Stake Reduction: Brown University's $8 billion endowment cut its stake in Blue Owl Capital by 53%, reducing shares from 3.2 million to 1.5 million as of March 31, 2025, indicating a cautious approach towards the private credit sector amid market uncertainties.
- Shareholding Status: Despite the reduction in Blue Owl Capital shares, the university retained approximately 2.6 million shares in the management company, reflecting confidence in the overall business despite challenging market conditions.
- Market Environment Impact: Publicly traded BDCs like OBDC are trading at significant discounts as investor skepticism about valuations grows, particularly with retail investors and wealthy individuals withdrawing from the private credit asset class due to negative headlines.
- Investment Return Performance: The endowment achieved an 11.9% investment return in fiscal 2025, demonstrating resilience in its diversified portfolio that spans public equity, real assets, and private equity, despite facing market pressures.
See More
BLUE OWL CAPITAL: DIVERSIFIED CAPITAL RAISING IN Q1 YIELDS $11 BILLION IN NEW COMMITMENTS ACROSS ASSET CLASSES, STRATEGIES, AND CHANNELS
Capital Raising Overview: Blue Owl Capital successfully diversified its capital raising efforts across various asset classes, strategies, and channels in Q1.
Commitments Achieved: The firm secured a total of $11 billion in new capital commitments during the first quarter.
See More
UBS Increases Target Price for Blue Owl Capital Inc. to $9.5, Up from $9
- UBS Raises Price Target: UBS has increased its price target for Blue Owl Capital from $9 to $9.50.
- Market Implications: This adjustment reflects UBS's positive outlook on Blue Owl Capital's performance and potential growth in the market.
See More
